Jim Cramer on Cheesecake Factory: 'There's A Lot to Like About This Story'
'I got another one for you, just kind of popped outta nowhere on my screen, Cheesecake Factory. Yeah, it's up over 31% year to date, trouncing the 6.5% gain in the S&P 500 over the same period, Cheesecake Factory. So once again, I'm asking what the heck is going on here… It's infamous for one thing, its ridiculously large menu…
A baker in a busy bakery, arranging freshly baked treats on a tray.
Cheesecake Factory (NASDAQ:CAKE) operates and licenses restaurant brands and manages bakery production for both internal use and external distribution. The company also supplies baked goods and cheesecakes to restaurants, retailers, and foodservice operators.
While we acknowledge the potential of CAKE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News
July 28 - Atai Life Sciences (NASDAQ:ATAI) shares slid 9% in pre?market trading on Monday after Recognify Life Sciences, an Atai?backed company, reported its Phase 2b trial of inidascamine for cognitive impairment linked to schizophrenia missed its primary endpoint. Warning! GuruFocus has detected 6 Warning Signs with ATAI. The oral compound, engineered to modulate multiple neurotransmitter pathways for pro?cognitive effects, failed to outperform placebo on key cognitive measures. Recognify said the results fell short of statistical significance. Atai's CEO acknowledged the setback but highlighted inidascamine's potential in CIAS and other indications. He added that Atai will redirect its efforts toward its wholly?owned psychedelic programs focused on affective disorders. Investors have been closely watching Atai's broader pipeline, which includes compounds targeting depression, PTSD and Alzheimer's disease. This latest trial disappointment adds to a string of mid?stage readouts that have tested market sentiment around biotech firms pivoting to next?generation neuroscience therapies. Despite today's drop, Atai's management reiterated its commitment to advancing its lead psychedelic candidates through upcoming Phase 1 and Phase 2 trials. Based on the one year price targets offered by 6 analysts, the average target price for ATAI Life Sciences NV is $9.83 with a high estimate of $12.00 and a low estimate of $7.00. The average target implies a upside of +175.44% from the current price of $3.57. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
Alibaba Stock Climbs on AI?Powered Smart Glasses Debut
July 28 - Shares of Alibaba (NYSE:BABA) climbed about 2% in early trading Monday after the e?commerce giant unveiled its first AI?powered smart glasses. Warning! GuruFocus has detected 2 Warning Signs with BABA. The Quark AI Glasses will arrive in China by year?end 2025, featuring hardware driven by Alibaba's Qwen large language model and its Quark AI assistant. Users can make hands?free calls, stream music, translate languages in real time and transcribe meetings via a built?in camera. Wearables stand as the next frontier alongside smartphones, and Alibaba aims to embed Quark more deeply into daily life. The glasses integrate with the company's ecosystem, offering navigation, Alipay payments and Taobao price comparisons without a phone. Alibaba faces a direct rivalry with Meta (NASDAQ:META) that partnered with Ray?Ban on its smart eyewear, and Chinese tech giant Xiaomi, whose own AI glasses appeared in early 2022. Hangzhou-based company has not disclosed the pricing or detailed specifications of the product, but the move highlights its aim at targeting consumer-level hardware and AI services. Shareholders will monitor how the new product can enable Alibaba to build a revenue diversification policy and strengthen revenues in its huge technology lineup. Based on the one year price targets offered by 38 analysts, the average target price for Alibaba Group Holding Ltd is $149.53 with a high estimate of $176.15 and a low estimate of $102.26. The average target implies a upside of +24.57% from the current price of $120.03. Based on GuruFocus estimates, the estimated GF Value for Alibaba Group Holding Ltd in one year is $111.74, suggesting a downside of -6.91% from the current price of $120.03. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
a few seconds ago
- Yahoo
IDEXX Laboratories (IDXX) Rallied in Q2. Here's Why
Conestoga Capital Advisors, an asset management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter began with a historically poor start but gained momentum later as tariff fears subsided and market volatility dropped precipitously. Conestoga Mid Cap Composite returned 3.46% net-of-fees in the quarter, trailing the Russell Mid Cap Growth Index's 18.20% return. After a strong first quarter in 2025, investor enthusiasm shifted towards high-beta and AI stocks following the "Liberation Day" announcements, creating a narrow leadership group that posed challenges for the Mid Cap Strategy in the second quarter. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as IDEXX Laboratories, Inc. (NASDAQ:IDXX). IDEXX Laboratories, Inc. (NASDAQ:IDXX) develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets. The one-month return of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was 5.38%, and its shares gained 19.58% of their value over the last 52 weeks. On July 25, 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock closed at $565.19 per share, with a market capitalization of $45.454 billion. Conestoga Capital Advisors stated the following regarding IDEXX Laboratories, Inc. (NASDAQ:IDXX) in its second quarter 2025 investor letter: "IDEXX Laboratories, Inc. (NASDAQ:IDXX) is the industry leader in providing instruments (and consumables) used in diagnostics, detection, and information systems for veterinary, food, and water testing applications. Earnings for the quarter were solid and guidance for high-single-digit organic revenue growth was maintained, despite weak traffic trends. Shares rallied off five-year low valuation and the 'better-than-feared' results in the quarter." A veterinarian in a veterinary clinic examining a companion animal. IDEXX Laboratories, Inc. (NASDAQ:IDXX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held IDEXX Laboratories, Inc. (NASDAQ:IDXX) at the end of the first quarter, which was 58 in the previous quarter. In the first quarter of 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported organic revenue growth of 5% driven by 4.5% organic revenue gains in the CAG business, 7% organic growth in water, and 4% organic growth in LPD. While we acknowledge the potential of IDEXX Laboratories, Inc. (NASDAQ:IDXX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered IDEXX Laboratories, Inc. (NASDAQ:IDXX) and shared Polen Focus Growth Strategy's views on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
